Mode
Text Size
Log in / Sign up

Protocol for natural experiment examining glucocorticoids versus no glucocorticoids on opioid use in hip and knee arthroplastyNew Plan to Cut Pain Meds After Joint Surgery

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note this is a protocol without results; clinical validity remains uncertain pending future data.

This study protocol outlines a natural experiment, specifically a target trial emulation, involving adults over 18 years old. The population consists of patients undergoing primary, elective total hip arthroplasty (THA), unicompartmental knee arthroplasty (UKA), and total knee arthroplasty (TKA) in the Capital Region and Region Zealand in Denmark. The sample size is not reported. The intervention involves a single high dose of glucocorticoids administered after induction of anaesthesia, while the comparator is no administration of glucocorticoids, though the control arm may have received a lower dose for postsurgical nausea and vomiting.

The primary outcome is opioid consumption measured in morphine equivalent doses during the first 24 hours after surgery. Secondary outcomes include the incidence of opioid-related adverse events, the incidence of serious adverse events, length of postoperative observation area-stay, length of hospital stay, and worst pain intensity-score. Follow-up for the primary outcome is the first 24 hours after surgery, while follow-up for other outcomes is not reported.

Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, are not reported as the study has not yet yielded results. A key limitation noted is that evidence based mainly on randomised controlled trials may have limited external clinical validity due to strict exclusion criteria. Funding or conflicts of interest are not reported. The practice relevance is not reported.

Causality is being examined, but results are not yet reported. The study is a protocol; results are not yet available. Do not overstate findings as this is a protocol without results. Do not infer clinical validity from RCTs with strict exclusion criteria without this real-world data.

Imagine waking up after hip surgery with less pain and fewer side effects.

Right now, many patients rely on strong opioids to manage pain. These drugs can cause nausea, drowsiness, and even addiction. Doctors want to find safer ways to help people heal faster.

Joint replacements are very common. Millions of people get hip or knee surgery every year. Pain is the biggest worry after the operation.

Current pain plans often use opioids. But these drugs have risks. Some patients need them for too long. Others get sick from the side effects.

Doctors need better tools. They want to reduce opioid use without making pain worse. This study looks at a different approach.

The Surprising Shift

We used to believe standard pain meds were the only way. High-dose steroids were used, but not always for pain.

Now, scientists are asking if a single big dose could help. They want to see if it works in real life.

But here is the twist. Most past studies were too strict. They left out older or sicker patients. This new plan looks at everyone.

Think of inflammation like a fire in your body. It makes joints swell and hurt.

Steroids act like a fire extinguisher. They put out the swelling quickly. This should lower pain signals to the brain.

The study tests if one big dose works better than small ones. It checks if this stops the need for opioids.

This research uses data from Denmark. It looks at adults over 18 having hip or knee surgery.

The team compares patients before and after the new rule started. They track pain medicine use for the first day.

They also watch for side effects like nausea or serious problems. The goal is to see if it is safe and helpful.

What They Hope to Find

Researchers expect opioid use to drop significantly. They want to see less pain reported by patients.

If successful, hospitals could change their standard care. Patients might leave the hospital sooner.

This doesn’t mean this treatment is available yet.

The team is waiting for the final numbers. They need to prove it works for everyone.

Real-World Data Explained

Most trials happen in perfect labs. This study uses real hospital records.

It includes people with other health issues. This makes the results more useful for you.

Experts say this is a smarter way to test treatments. It shows how drugs work in daily life.

You cannot get this treatment right now. The study is still in the planning phase.

Talk to your surgeon about pain options. Ask if steroids are part of your plan.

Wait for the final results before making changes. Safety is the top priority.

This is a protocol, not finished results. We do not know the outcome yet.

The study relies on past hospital data. Some details might be missing.

Results could change when the full analysis is done. We must wait for the final report.

The team will share results at medical conferences. They plan to publish the full report soon.

More studies might follow to confirm the findings. Approval for new uses takes time.

Patients should stay tuned for updates from trusted medical sources.

Study Details

Study typeRct
EvidenceLevel 2
PublishedApr 2026
View Original Abstract ↓
IntroductionHigh-dose glucocorticoids are increasingly used in patients undergoing primary total hip arthroplasty (THA), unicompartmental knee arthroplasty (UKA), and total knee arthroplasty (TKA). However, the evidence supporting the use of high-dose glucocorticoids to manage acute postoperative pain is based mainly on randomised controlled trials, which may have limited external clinical validity due to strict exclusion criteria. In Denmark, the treatment was implemented stepwise, comprising a natural experiment. ObjectiveTo examine the real-world effect of a single dose of high-dose glucocorticoids on postoperative opioid consumption and adverse events in patients undergoing THA, UKA, and TKA. MethodsThis protocol describes a natural experiment study that will be reported as a target trial emulation, i.e. by attempting to mimic a randomised clinical trial. Inclusion and exclusion criteriaAll adults (>18 years) undergoing primary, elective THA, UKA, and TKA in the Capital Region and Region Zealand in Denmark are eligible. At each centre, patients who underwent surgery within one year before and one year after the implementation of high-dose glucocorticoids are screened for eligibility. InterventionThe intervention is the intended use of a single high dose of glucocorticoids, administered after induction of anaesthesia, as part of the standard treatment. ComparatorThe comparator is no administration of glucocorticoids. Patients in the control arm may have received a lower dose of glucocorticoids for postsurgical nausea and vomiting Assignment of interventionFor each hospital, patients who underwent surgery before the implementation of glucocorticoids serve as controls, while patients operated on after the implementation constitute the treatment arm. OutcomesThe primary outcome is opioid consumption, expressed in morphine equivalent doses (MEQs) in the first 24 hours after surgery. Secondary outcomes are two adverse effect-outcomes: incidence of opioid-related adverse events and serious adverse events, and three efficacy-outcomes: length of postoperative observation area-stay, length of hospital stay, and worst pain intensity-score measured. Data collectionThis study uses data from the TRIPLE-A project (www.triplea.dk), comprising validated electronic health record data. Statistical analysesThe analyses will be based on a pre-defined mixed effects model with hospital as a random effect and adjusted for important presurgical (and thus pre-intervention) variables. A per protocol population will be analysed as a sensitivity analysis. For the primary outcome, a difference of 5 MEQs between treatment arms is considered clinically important. Knowledge disseminationThe results will be shared at conferences and made publicly available. Registrationhttps://doi.org/10.1101/2025.11.11.25339982
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.